Filter by:
Revita
DDW, 2022
Improvements In Insulin Sensitivity Seen In Patients With Type 2 Diabetes After Revita® DMR Are Associated With A Decrease In Glucagon, Glucose, And GIP After A Mixed Meal Tolerance Test
Meiring, et al. presented at Digestive Disease Week (DDW) 2022, San Diego, CA, USA, May 2022
Revita
Cardiovascular Diabetology, 2022.
Eliminating exogenous insulin therapy in patients with type 2 diabetes by duodenal ablation and GLP-1 RA decreases risk scores for cardiovascular events
Meiring, et al.
Revita
Diabetes Research and Clinical Practice, 13 January 2022.
Durable metabolic improvements 2 years after duodenal mucosal resurfacing (DMR) in patients with type 2 diabetes (REVITA-1 Study)
van Baar, et al.
Revita
American Journal of Physiology, Endocrinology and Metabolism, 31 January 2022.
Duodenal mucosal resurfacing with a GLP-1 receptor agonist increases postprandial unconjugated bile acids in patients with insulin-dependent type 2 diabetes
Meiring, et al.
Revita
Frontiers in Clinical Diabetes and Healthcare, 05 July 2022.
A Changed Gut Microbiota Diversity Is Associated With Metabolic Improvements After Duodenal Mucosal Resurfacing With Glucagon-Like-Peptide-1 Receptor Agonist in Type 2 Diabetes in a Pilot Study
Meiring, et al.
Revita
Journal of Diabetes Science and Technology, October 2021.
A Gut-Centric Model of Metabolic Homeostasis
Rajagopalan, et al.
Revita
DDW, May 2021
Changes in Incretins Bile acids and the Microbiome after duodenal mucosal resurfacing in patients with Type 2 Diabetes
Meiring, et al. presented at Digestive Disease Week (DDW) 2021, Virtual, May 2021
Revita
Gut, January 2021.
Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial
Mingrone, et al.
Revita
Gastrointestinal Endoscopy, December 2020.
Duodenal mucosal resurfacing combined with GLP-1RA to discontinue insulin in type 2 diabetes: a feasibility study
van Baar, et al.